Quest Diagnostics Launches Novel Prostate Cancer Test Aimed At Improving Diagnosis And Grading
Portfolio Pulse from Happy Mohamed
Quest Diagnostics (NYSE:DGX) has launched a novel prostate cancer biomarker test in collaboration with Envision Sciences. The test, developed through Quest's subspecialty pathology business AmeriPath, aims to improve the diagnosis and grading of prostate cancer. The test uses Envision's proprietary biomarker and immunohistochemistry technology, which has shown to upgrade 22% of tissue specimens and downgrade 20% compared to conventional assessment methods. The test is available for order by physicians in the United States, excluding New York.
July 13, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has launched a new prostate cancer test, which could potentially improve the company's market position in the diagnostic services sector. The test's success could lead to increased demand for Quest's services.
The launch of a novel prostate cancer test by Quest Diagnostics could potentially improve the company's market position in the diagnostic services sector. If the test proves successful and is adopted widely, it could lead to increased demand for Quest's services, positively impacting the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100